Form 4: GlycoMimetics Director Acquires 40,000 Stock Options
SEC Filing
A Form 4 filing reveals that GlycoMimetics director Scott Koenig acquired 40,000 stock options on May 1, 2024.
Summary
- On May 1, 2024, Scott Koenig, a director of GlycoMimetics Inc. (GLYC), acquired 40,000 stock options.
- The exercise price of these options is $1.62.
- The options vest on May 1, 2025, contingent upon continuous service.
- The options expire on April 30, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of options by a director is generally viewed as a positive, but it's not a strong indicator on its own.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's activity in acquiring company stock options, which is a common form of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Date of transaction: Scott Koenig acquired 40,000 stock options. |
| 05/01/2025 | Vesting date for the stock options, contingent upon continuous service. |
| 04/30/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.